Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from GNI Group ( (JP:2160) ) is now available.
GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has completed subject enrollment for a Phase 3 clinical trial of Pirfenidone Capsule, aimed at treating pneumoconiosis. This trial, conducted across 18 centers in China, evaluates the drug’s efficacy and safety over 52 weeks. The completion of enrollment marks a significant step in the development of treatments for this chronic lung disease, although the financial impact on GNI Group’s current fiscal year is expected to be minimal.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development of new drug therapies. Its key subsidiary, Gyre Therapeutics, is involved in clinical trials and research, particularly in the area of respiratory diseases.
Average Trading Volume: 1,286,958
Technical Sentiment Signal: Hold
Current Market Cap: Yen129.6B
For a thorough assessment of 2160 stock, go to TipRanks’ Stock Analysis page.